Clinical Trial Update: A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for MIL62 combined with Orelabrutinib in relapsed/refractory B-cell lymphoma (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• MIL62
• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory | Phase 1, Phase 2 | Status: UNKNOWN